EyePoint tumbles after experimental eye drug misses main goal in late-stage study
EYPT•Next study data and filing timeline
The company expects data from a second late-stage wet AMD study in Q4 2026 and plans a potential FDA filing in H1 2027.
As of the last close, the stock was down about 19% year to date.
EyePoint shares fall after Duravyu misses primary endpoint
Shares of drug developer EyePoint EYPT.O fell 62.7% to $5.50 premarket.
The company said experimental eye drug Duravyu missed the main goal of a late-stage trial against Regeneron's blockbuster eye drug Eylea in patients with wet age-related macular degeneration, a leading cause of vision loss.
Company highlights secondary analyses and treatment burden reduction
EyePoint said an analysis excluding nine patients whose vision loss was unrelated to wet AMD showed Duravyu performed similarly to Eylea.
The company also said Duravyu reduced treatment burden by 42% versus Eylea, or about two fewer injections through Week 56.
EyePoint said 54% of patients were supplement-free through Week 56 and 79% received zero or one supplemental injection.
